All In Biotech

Drug Trial Radar · NCT03588299

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Nov 7, 2018

Primary completion

Sep 15, 2026

Study completion Sep 15, 2026

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Ultragenix pharmaceutical
First posted
Jul 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.

Conditions

  • Hemophilia A

Interventions

  • BAY2599023 (DTX201)Drug

    Single escalating doses with 4 dose steps; Single intravenous (IV) administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and AEs/SAEs of special interestTime frame: Up to 5 years.

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital - Hematology / Oncology

    Little Rock, Arkansas

  • C.S. Mott Children's Hospital - Hematology / Oncology

    Ann Arbor, Michigan

  • UW Health Carbone Cancer Center

    Madison, Wisconsin

  • SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD

    Sofia, Sofia City Province, Bulgaria

  • CHU Rennes - Hopital Pontchaillou

    Rennes, Brittany Region, France

  • APHP-Hopital Necker Enfants malades

    Paris, Île-de-France Region, France

  • Universitätsklinikum des Saarlandes

    Homburg, Saarland, Germany

  • Vivantes Klinikum im Friedrichshain

    Berlin, State of Berlin, Germany

  • Academisch Medisch Centrum (AMC)

    Amsterdam, North Holland, Netherlands

  • Universitair Medisch Centrum Groningen

    Groningen, Provincie Groningen, Netherlands

  • Erasmus Medisch Centrum

    Rotterdam, South Holland, Netherlands

  • University Medical Center Utrecht

    Utrecht, Utrecht, Netherlands

  • Manchester Royal Infirmary | Haematology

    Manchester, Greater Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.